Equities

Tauns Laboratories Inc

197A:TYO

Tauns Laboratories Inc

Actions
Health CareMedical Equipment and Services
  • Price (JPY)569.00
  • Today's Change-6.00 / -1.04%
  • Shares traded784.50k
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Nov 15 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Jun 30 2024202420232022
ASSETS
Cash And Short Term Investments9,4251,2446,347
Total Receivables, Net2,7233,481942
Total Inventory4,7174,5874,588
Prepaid expenses48130141
Other current assets, total2.531517
Total current assets16,9169,45712,036
Property, plant & equipment, net7,9054,4023,683
Goodwill, net------
Intangibles, net3,7213,9104,138
Long term investments672518363
Note receivable - long term07777
Other long term assets42(33)(29)
Total assets29,26118,33220,268
LIABILITIES
Accounts payable1,4831,1431,391
Accrued expenses1,0102681,264
Notes payable/short-term debt4,5003,5001,200
Current portion long-term debt/capital leases732732732
Other current liabilities, total2,7508754,350
Total current liabilities10,4746,5188,937
Total long term debt4,3072,2362,968
Total debt9,5396,4684,900
Deferred income tax619922867
Minority interest------
Other liabilities, total194166140
Total liabilities15,5959,84212,912
SHAREHOLDERS EQUITY
Common stock206100100
Additional paid-in capital2,6832,7832,783
Retained earnings (accumulated deficit)10,7865,6144,477
Treasury stock - common------
Unrealized gain (loss)(7.98)(7)(3.9)
Other equity, total0.00----
Total equity13,6678,4907,356
Total liabilities & shareholders' equity29,26118,33220,268
Total common shares outstanding100100100
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.